Kura Oncology to Showcase Darlifarnib-Cabozantinib Data in Kidney Cancer Trial
Event summary
- Kura Oncology will present updated data from the FIT-001 trial at IKCS Europe 2026 on April 17, 2026.
- The data builds on earlier findings from the 2025 ESMO Congress, showing promising activity of darlifarnib plus cabozantinib in advanced renal cell carcinoma.
- Darlifarnib is designed to inhibit farnesylation of RHEB and suppress mTORC1 signaling, potentially enhancing the activity of VEGFR-targeted therapies like cabozantinib.
- Kura will host a virtual investor call on April 17, 2026, at 7:30 a.m. PT.
The big picture
Kura Oncology's presentation at IKCS Europe 2026 highlights the ongoing shift towards combination therapies in precision oncology. The focus on overcoming resistance to existing treatments like cabozantinib aligns with broader industry trends towards more effective and targeted cancer therapies. The success of darlifarnib could position Kura as a key player in the renal cell carcinoma treatment space, potentially attracting partnerships or investment.
What we're watching
- Clinical Efficacy
- How the updated data from the FIT-001 trial will impact the perceived potential of darlifarnib in overcoming resistance to VEGFR TKI therapy.
- Regulatory Pathway
- Whether the promising results will accelerate the regulatory approval process for darlifarnib in combination with cabozantinib.
- Market Positioning
- The pace at which Kura Oncology can differentiate itself in the competitive landscape of precision oncology treatments.
Related topics